Sales and Marketing

Showing 15 posts of 11528 posts found.

Revolade gets European go ahead

March 15, 2010 Sales and Marketing GlaxoSmithKline, Revolade, thrombocytopenia

European regulators have approved GlaxoSmithKline’s Revolade to treat reduced platelet count in patients with a rare blood disorder. Revolade (eltrombopag) …

FDA strengthens Plavix safety warning

March 15, 2010 Sales and Marketing Plavix

A boxed warning has been added to the US packaging of Sanofi-Aventis and Bristol-Myers Squibb’s blockbuster anti-clotting drug Plavix. The …
GSKstephenne

GSK promotes Jean Stephenne to chairman, biologicals

March 15, 2010 Research and Development, Sales and Marketing GlaxoSmithKline, appointment, research and development, sales and marketing

GlaxoSmithKline has appointed Jean Stephenne chairman of GSK Biologicals, the company’s global vaccines division.He is currently president and general manager of …
Ratiopharm HQ

Pfizer muscles in on Ratiopharm sale

March 11, 2010 Sales and Marketing Pfizer, Ratiopharm, Teva, generics

Pfizer has reportedly bid $4 billion for German generics firm Ratiopharm in a bid to rapidly expands its portfolio in …

Teva appoints Dr Phillip Frost chairman

March 11, 2010 Sales and Marketing Teva, appointment, sales and marketing

Teva Pharmaceutical Industries has appointed Dr Phillip Frost as chairman of the board of directors. His appointment is part of …

Investments boost Irish pharma sector

March 11, 2010 Research and Development, Sales and Marketing Ireland, PPD, Warner Chilcott

Contract research organisation PPD has officially opened its new research laboratory in Athlone, Ireland, and started recruiting for the first …

German Health Minister attacks ‘pharma monopoly’

March 10, 2010 Sales and Marketing Germany, cost-effectiveness, price cuts, prices

German Health Minister Philipp Rösler wants to break pharma’s ‘monopolistic hold’ over the country by introducing price limits on new …

Five-year cardiovascular study planned for Onglyza

March 10, 2010 Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes

Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …

Abbott boosts pipeline with biotech acquisition

March 10, 2010 Research and Development, Sales and Marketing Abbott, Facet Biotech, daclizumab, volociximab

Abbott is to acquire US company Facet Biotech in a $450 million deal that will boost its oncology and immunology …

Eusa Pharma appoints Iain McGill

March 10, 2010 Sales and Marketing Eusa Pharma, appointment, sales and marketing

Iain McGill has joined specialty company Eusa Pharma as international and European president. He moves to Eusa from Wyeth Pharmaceutical, …

Sanofi and Merck to merge animal health businesses

March 9, 2010 Sales and Marketing Merck, Sanofi, animal health

Sanofi-Aventis and Merck have announced a joint venture, bringing together their animal health businesses Merial and Intervet/Schering-Plough.  The company’s say …

Vidaza too costly for NICE

March 8, 2010 Sales and Marketing Celgene, NICE, Vidaza

NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …

Orphan and rare disease marketers: are you armed for success?

March 8, 2010 Business Services, Sales and Marketing Orphan

Many marketers are currently unfamiliar with the specific approaches required in orphan and rare disease (ORD) brands, but will need …
MabThera

Roche cancer drug gets NICE thumbs up

March 5, 2010 Sales and Marketing MabThera, Roche

NICE has recommended Roche’s MabThera to treat patients with the most common form of leukaemia, relapsed or refractory chronic lymphocytic …

NICE asks Roche for RoActemra cost data

March 5, 2010 Sales and Marketing RoActemra, Roche

Roche’s attempts to secure NICE approval for rheumatoid arthritis drug RoActemra have hit another hurdle. NICE’s independent appraisal committee has …
The Gateway to Local Adoption Series

Latest content